Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain

Journal of Clinical Virology

Volumn 33, Issue 3, 2005, Pages 224-229

  Muñoz, Mercedes ^a   Carmona, Rocío ^a   Pérez Alvarez, Lucía ^a   Cilla, Gustavo ^b   Suarez, María Dolores ^c   Delgado, Elena ^a   Contreras, Gerardo ^a   Corral, Jesús ^d   López De Goicoetxea, María José ^e   Medrano, Leandro ^a   Lezaún, María Jesús ^f   Nájera, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL DE CRUCES   (Spain)

^e HOSPITAL DE GALDAKAO   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Antiretrovirals; Discrepancies; Genotypic analysis; HIV 1; Phenotypic analysis; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RNA EXTRACTION; SEQUENCE ANALYSIS; SPAIN; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN;

ALGORITHMS; ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SOFTWARE;

EID: 21144431829     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.06.014     Document Type: Article

References (20)

1. A. De Luca, and C.F. Perno Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing Curr Opin Infect Dis 16 2003 573 580
2. L. Demeter, and R. Haubrich Phenotypic and genotypic resistance assays: methodology, reliability and interpretations J Acquir Immune Defic Syndr 26 2001 S3 S9
3. A.L. Dunne, F.M. Mitchell, and S.K. Coberty Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs AIDS 15 2001 1471 1474
4. EuroGuidelines Group for HIV Resistance, 2003. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS;17: S3-S26.
5. M.S. Hirsch, F. Brun-Vezinet, and B. Clotet Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel Clin Infect Dis 37 1 2003 113 128
6. G.H. Kijak, A.E. Rubio, and S.E. Pampuro Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms HIV Med 4 2003 75 78
7. J.L. Meynard, M. Vray, and L. Morand-Joubert Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial AIDS 16 2002 727 736
8. N.T. Parkin, C. Chappey, and C.J. Petropoulos Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance AIDS 17 2003 955 961
9. L. Pérez-Alvarez, R. Carmona, and M. Muñoz Discrepant results between antiretroviral resistance mutations patterns by genotypic analysis (Stanford HIV-Seq Program) and Virtual Phenotype (VircoNet). First European HIV Drug Resistance Workshop, Luxemburg, 6-8 March HIV Med 4 2003 23
10. E. Puchhammer-Stockl, C. Steininger, and E. Geringer Comparison of virtual phenotype and HIV-SEQ program/Stanford) interpretation for predicting drug resistance of HIV strains HIV Med 3 2002 200 206
11. J. Ravela, B.J. Betts, and F. Brun-Vézinet HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms J Acquir Immune Defic Syndr 33 2003 8 14
12. C. Reid, R. Bassett, and S. Day A dynamic rules-based interpretation system derived by an expert panel is predictive of virological failure Antiviral Ther 6 2001 21 39
13. B. Schmidt, H. Walter, and E. Schwingel Comparison of different interpretation systems for genotypic HIV-1 drug resistance data Antiviral Ther 6 2001 102
14. R.W. Shafer, D.R. Jung, and B.J. Betts Human immunodeficiency virus reverse transcriptase and protease sequence database Nucleic Acids Res 28 2000 346 348
15. M. Sturmer, H.W. Doerr, and S. Staszewski Comparison of nine resistance interpretation systems for HIV-1 genotyping Antiviral Ther 8 2003 239 244
16. C. Torti, E. Quiros-Roldan, and W. Keulen Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients J Infect Dis 188 2003 194 201
17. A.M. Vandamme, K. Van Laethem, and E. De Clercq Managing resistance to anti-HIV drugs: an important consideration for effective disease management Drugs 57 3 1999 337 361
18. K. Van Laethem, A. De Luca, and A. Antinori A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients Antiviral Ther 7 2002 123 129
19. M.L. Villahermosa, M. Thomson, and E. Vázquez de Parga Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load J Hum Virol 3 2000 27 34
20. A.R. Zolopa Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance AIDS 17 2003 1077 1078